会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US07919512B2
    • 2011-04-05
    • US12828800
    • 2010-07-01
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/44C07D401/00
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(II)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 8. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US07750027B2
    • 2010-07-06
    • US12625497
    • 2009-11-24
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/4439C07D401/06
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(I)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 9. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US08563536B2
    • 2013-10-22
    • US13017860
    • 2011-01-31
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/70A61K31/56A61K31/50A61K31/47A61K31/44
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (II) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(II)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。
    • 10. 发明授权
    • Compounds having CRTH2 antagonist activity
    • 具有CRTH2拮抗活性的化合物
    • US08536158B2
    • 2013-09-17
    • US13014314
    • 2011-01-26
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • Richard Edward ArmerEric Roy PettipherMark WhittakerGraham Michael WynneJulia VileFrank Schroer
    • A61K31/70A61K31/56A61K31/50A61K31/47A61K31/44
    • A61K31/4439A61K31/47A61K45/06C07D401/06
    • Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents, selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, or —O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(═O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C═O)R6)2; m is 1 or 2; n is 1-4; X is OR5 or N(R5)2; R5 is hydrogen or methyl; and R6 is C1-C18 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(I)的化合物,其中W是氯或氟; R 1是任选被一个或多个选自卤素,-CN,-C 1 -C 6烷基,-SOR 3,-SO 2 R 3,-SO 2 N(R 2)2,-N(R 2)2,-NR 2 C(O)R 3 ,-CO 2 R 2,-CONR 2 R 3,-NO 2,-OR 2,-SR 2,-O(CH 2)pOR 2或-O(CH 2)p O(CH 2)q OR 2,其中每个R 2独立地是氢,-C 1 -C 6烷基, C8环烷基,芳基或杂芳基; 每个R 3独立地是-C 1 -C 6烷基,-C 3 -C 8环烷基,芳基或杂芳基; p和q各自独立地为1至3的整数; 芳基,(CH2)mOC(= O)C1-C6烷基,((CH2)mO)nCH2CH2X,(CH2)mN(R5)2或CH ((CH 2)m O(C = O)R 6)2; m为1或2; n为1-4; X为OR 5或N(R 5)2; R5是氢或甲基; R6为C1-C18烷基; 其药学上可接受的盐,水合物,溶剂合物,复合物或前药可用于口服给药的组合物中,用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。